Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial
James W. Murrough, Laili Soleimani, Kaitlin E. DeWilde, et al.
Psychological Medicine (2015) Vol. 45, Iss. 16, pp. 3571-3580
Closed Access | Times Cited: 276

Showing 26-50 of 276 citing articles:

A Brain-Centric Model of Suicidal Behavior
J. John Mann, Mina Rizk
American Journal of Psychiatry (2020) Vol. 177, Iss. 10, pp. 902-916
Open Access | Times Cited: 141
Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review
Zach Walsh, Özden Merve Mollaahmetoğlu, Joseph M. Rootman, et al.
BJPsych Open (2021) Vol. 8, Iss. 1
Open Access | Times Cited: 124
Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
Ioline D. Henter, Lawrence T. Park, Carlos A. Zarate
CNS Drugs (2021) Vol. 35, Iss. 5, pp. 527-543
Open Access | Times Cited: 108
Eradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors
Domenico De Berardis, Michele Fornaro, Alessandro Valchera, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 10, pp. 2888-2888
Open Access | Times Cited: 159
Ketamine versus midazolam in bipolar depression with suicidal thoughts: A pilot midazolam‐controlled randomized clinical trial
Michael F. Grunebaum, Steven P. Ellis, John G. Keilp, et al.
Bipolar Disorders (2017) Vol. 19, Iss. 3, pp. 176-183
Closed Access | Times Cited: 156
NMDA Receptors in the Central Nervous System
Kasper B. Hansen, Feng Yi, Riley E. Perszyk, et al.
Methods in molecular biology (2017), pp. 1-80
Open Access | Times Cited: 151
Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments
Bashkim Kadriu, Laura Musazzi, Ioline D. Henter, et al.
The International Journal of Neuropsychopharmacology (2018) Vol. 22, Iss. 2, pp. 119-135
Open Access | Times Cited: 144
Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials
Elizabeth D. Ballard, Kathleen E. Wills, Níall Lally, et al.
Journal of Affective Disorders (2017) Vol. 218, pp. 195-200
Open Access | Times Cited: 134
Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism
Nolan Williams, Boris D. Heifets, Brandon S. Bentzley, et al.
Molecular Psychiatry (2019) Vol. 24, Iss. 12, pp. 1779-1786
Closed Access | Times Cited: 132
Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression
Marc S. Lener, Bashkim Kadriu, Carlos A. Zarate
Drugs (2017) Vol. 77, Iss. 4, pp. 381-401
Open Access | Times Cited: 123
An update on ketamine and its two enantiomers as rapid-acting antidepressants
Kai Zhang, Kenji Hashimoto
Expert Review of Neurotherapeutics (2018) Vol. 19, Iss. 1, pp. 83-92
Closed Access | Times Cited: 123
KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE
William V. Bobo, Jennifer L. Vande Voort, Paul E. Croarkin, et al.
Depression and Anxiety (2016) Vol. 33, Iss. 8, pp. 698-710
Open Access | Times Cited: 117
Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants
Todd D. Gould, Carlos A. Zarate, Scott M. Thompson
The Annual Review of Pharmacology and Toxicology (2018) Vol. 59, Iss. 1, pp. 213-236
Open Access | Times Cited: 117
Ketamine for treatment-resistant depression: recent developments and clinical applications: Table 1
Jaclyn Schwartz, James W. Murrough, Dan V. Iosifescu
Evidence-Based Mental Health (2016) Vol. 19, Iss. 2, pp. 35-38
Open Access | Times Cited: 111
Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression
Jennifer L. Phillips, Sandhaya Norris, Jeanne Talbot, et al.
Neuropsychopharmacology (2019) Vol. 45, Iss. 4, pp. 606-612
Open Access | Times Cited: 111
Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials
Joanna Kryst, Paweł Kawalec, Alicja Mikrut Mitoraj, et al.
Pharmacological Reports (2020) Vol. 72, Iss. 3, pp. 543-562
Open Access | Times Cited: 111
Ketamine applications beyond anesthesia – A literature review
Agata Nowacka, Małgorzata Borczyk
European Journal of Pharmacology (2019) Vol. 860, pp. 172547-172547
Closed Access | Times Cited: 102
Pharmacological treatment of eating disorders, comorbid mental health problems, malnutrition and physical health consequences
Hubertus Himmerich, Carol Kan, Katie Au, et al.
Pharmacology & Therapeutics (2020) Vol. 217, pp. 107667-107667
Closed Access | Times Cited: 101
Essential role of microglial transforming growth factor-β1 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-β1
Kai Zhang, Chun Yang, Lijia Chang, et al.
Translational Psychiatry (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 100
Administration of ketamine for unipolar and bipolar depression
Christoph Kraus, Ulrich Rabl, Thomas Vanicek, et al.
International Journal of Psychiatry in Clinical Practice (2017) Vol. 21, Iss. 1, pp. 2-12
Closed Access | Times Cited: 99
The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis
Jiaqi Xiong, Orly Lipsitz, David Chen‐Li, et al.
Journal of Psychiatric Research (2020) Vol. 134, pp. 57-68
Closed Access | Times Cited: 95
A Circadian Genomic Signature Common to Ketamine and Sleep Deprivation in the Anterior Cingulate Cortex
Ricardo Orozco-Solís, Emilie Montellier, Lorena Aguilar‐Arnal, et al.
Biological Psychiatry (2017) Vol. 82, Iss. 5, pp. 351-360
Open Access | Times Cited: 94
Precision medicine for suicidality: from universality to subtypes and personalization
Alexander B. Niculescu, H Le-Niculescu, Daniel F. Levey, et al.
Molecular Psychiatry (2017) Vol. 22, Iss. 9, pp. 1250-1273
Open Access | Times Cited: 87
Glutamatergic Modulators in Depression
Ioline D. Henter, Rafael T. de Sousa, Carlos A. Zarate
Harvard Review of Psychiatry (2018) Vol. 26, Iss. 6, pp. 307-319
Open Access | Times Cited: 86
Prophylactic use of ketamine reduces postpartum depression in Chinese women undergoing cesarean section✰
Jiahui Ma, Saiying Wang, He‐Ya Yu, et al.
Psychiatry Research (2019) Vol. 279, pp. 252-258
Closed Access | Times Cited: 86

Scroll to top